Trevi Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Rosalind Advisors, Inc.(1.98%),Steven Salamon(1.98%)等
Trevi Therapeutics | SCHEDULE 13G/A:其他
Trevi Therapeutics | 4:持股变动声明-董事 Mathers Edward T
Trevi Therapeutics | 4:持股变动声明-董事 Meeker David P
Trevi Therapeutics | 4:持股变动声明-董事 Heffernan Michael Thomas
Trevi Therapeutics | 4:持股变动声明-董事 Cassella James V
Trevi Therapeutics | 4:持股变动声明-董事 Colangelo Dominick
Trevi Therapeutics | 8-K:重大事件
Trevi Therapeutics | 4:持股变动声明-高管 SCIASCIA THOMAS
Trevi Therapeutics | 144:拟议出售证券
Trevi Therapeutics | 4:持股变动声明-高管 Delfini Lisa
Trevi Therapeutics | 4:持股变动声明-高管 GOOD JENNIFER L
Trevi Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-New Enterprise Associates 16, L.P.(20.3%),NEA Partners 16, L.P.(20.3%)等
Trevi Therapeutics | 4:持股变动声明-高管 GOOD JENNIFER L
Trevi Therapeutics | 10-Q:季度报表
Trevi Therapeutics | 8-K:Trevi Therapeutics公布2024年第一季度财务业绩并提供业务最新情况
Trevi Therapeutics | ARS:年度报告
Trevi Therapeutics | DEFA14A:其他
Trevi Therapeutics | DEF 14A:股东委托书决议
Trevi Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Rosalind Advisors, Inc.(1.34%),Steven Salamon(1.34%)等
暂无数据